Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 1.00 |
| ▸ | PGR | P06401 | 6/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Al-43 SCHEMBL4172433 | 1.00 | NR3C1 (1.00) | NR3C1PGRAR | |
| Al-43 SCHEMBL7110788 | 1.00 | NR3C1 (1.00) | NR3C1PGRAR | |
| Al-43 SCHEMBL7132239 | 0.93 | NR3C1 (0.85) | NR3C1PGRAR | |
| SCHEMBL6294343 | 0.91 | NR3C1 (1.00) | NR3C1PGRAR | |
| SCHEMBL4170535 | 0.91 | NR3C1 (1.00) | NR3C1PGRAR | |
| SCHEMBL4172432 | 0.91 | NR3C1 (1.00) | NR3C1PGRAR | |
| SCHEMBL4186130 | 0.91 | NR3C1 (0.83) | NR3C1PGRAR | |
| SCHEMBL6291135 | 0.90 | NR3C1 (1.00) | NR3C1PGRAR | |
| SCHEMBL4179264 | 0.90 | NR3C1 (1.00) | NR3C1PGRAR | |
| SCHEMBL4170282 | 0.90 | NR3C1 (1.00) | NR3C1PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366632-A1 | METHODS FOR THE TREATMENT OF OCULAR ROSACEA | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-11-07 | — | — | US | claimed |
| EP-4395785-A1 | METHODS FOR THE TREATMENT OF OCULAR ROSACEA | Inserm (Institut National de la Santé et de la Recherche Scientifique) (FR) | 2024-07-10 | — | — | EP | claimed |
| CN-114318201-B | Control method for molten pool zinc slag of aluminum zinc pot in continuous hot dip aluminum zinc plating production line | 上海梅山钢铁股份有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-114316809-B | Sealant for lithium battery and preparation method thereof | 南亚新材料科技股份有限公司 | 2023-10-20 | — | — | CN | claimed |
| WO-2023031277-A1 | METHODS FOR THE TREATMENT OF OCULAR ROSACEA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-03-09 | — | — | WO | claimed |
| CN-114318201-A | Control method of zinc slag in molten pool of aluminum-zinc pot of continuous hot-dip aluminum-zinc plating production line | 上海梅山钢铁股份有限公司 | 2022-04-12 | — | — | CN | claimed |
| EP-4745209-A1 | LAMINATE AND ELECTRICAL INSULATION SHEET FOR MOTORS | Toray Industries, Inc. (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-12630752-B2 | Epoxy resin adhesive for medical device and cured product of the same, and medical device member and medical device | FUJIFILM CORPORATION (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4725558-A2 | IMMUNOABLATIVE THERAPIES | AVM Biotechnology, LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4720182-A1 | SILICONE ELASTOMER FOR DIELECTRIC ACTUATORS, HAVING PROLONGED SERVICE LIFE | Wacker Chemie AG (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-3860612-B1 | IMMUNOABLATIVE THERAPIES | AVM BIOTECHNOLOGY LLC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260035563-A1 | POLYSILOXANE FILLER TREATING AGENT AND COMPOSITIONS PREPARED THEREWITH | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260015463-A1 | POLYSILOXANE FILLER TREATING AGENT AND COMPOSITIONS PREPARED THEREWITH | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-01-15 | — | — | US | disclosed |
| CN-114318201-A | Control method of zinc slag in molten pool of aluminum-zinc pot of continuous hot-dip aluminum-zinc plating production line | 上海梅山钢铁股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3971235-A1 | STABILIZED MATRIX-FILLED LIQUID RADIATION CURABLE RESIN COMPOSITIONS FOR ADDITIVE FABRICATION | Covestro (Netherlands) B.V. (NL) | 2022-03-23 | — | — | EP | disclosed |
| CN-114196303-A | Intelligent power module and radiating fin for same | 苏州赛伍应用技术股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022051583-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OREXIA THERAPEUTICS LIMITED (GB) | 2022-03-10 | — | — | WO | disclosed |
| US-11253594-B2 | Drug combinations for protecting against neuronal cell death | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220033553-A1 | COMPOSITIONS AND ARTICLES FOR ADDITIVE FABRICATION AND METHODS OF USING THE SAME | STRATASYS INC. | 2022-02-03 | — | — | US | disclosed |
| CN-109503761-B | Stable matrix-filled liquid radiation curable resin compositions for additive fabrication | 科思创(荷兰)有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035563-A1 | POLYSILOXANE FILLER TREATING AGENT AND COMPOSITIONS PREPARED THEREWITH | H1-0, COL1A1, H1-2 | NR3C1 90/4885PGR 527/4885AR 1089/4885 |
| US-12630752-B2 | Epoxy resin adhesive for medical device and cured product of the same, and medical device member and medical device | PIEZO1, EED, SRM | NR3C1 3890/4885PGR 385/4885AR 1720/4885 |
| US-11253594-B2 | Drug combinations for protecting against neuronal cell death | NLN, CASP3, BAX | NR3C1 2129/4885PGR 3691/4885AR 4565/4885 |
| US-20260015463-A1 | POLYSILOXANE FILLER TREATING AGENT AND COMPOSITIONS PREPARED THEREWITH | H1-0, COL1A1, RER1 | NR3C1 800/4885PGR 1764/4885AR 3654/4885 |
| US-20240366632-A1 | METHODS FOR THE TREATMENT OF OCULAR ROSACEA | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 30/4885AR 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.